Search

everythinglearnresearchcommunity

for

Search:↓

Corni Fructus extract may help manage benign prostatic hyperplasia by reducing prostate cell growth and inflammation.

Zapoteca portoricensis extract may help protect against prostate issues and support liver and kidney health in rats.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Herbal products for benign prostate hypertrophy need better quality checks to ensure safety and effectiveness.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Urban living may increase prostate cancer risk, while early sexual activity might reduce it.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

New curcumin analogues help fight prostate cancer by breaking down androgen receptors.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

The normal human prostate does not significantly affect blood DHT levels.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.

The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.

Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.

Urban living may increase prostate cancer risk, while early sexual activity might reduce it.

Phytosterols may help manage prostate issues but are less effective than synthetic drugs.